Effect of Carvedilol on Heart Failure in Patients With a Functionally Univentricular Heart
-
- Ishibashi Naoko
- Department of Pediatrics, Sakakibara Heart Institute
-
- Park In-Sam
- Department of Pediatrics, Sakakibara Heart Institute
-
- Waragai Tadashi
- Department of Pediatrics, Sakakibara Heart Institute
-
- Yoshikawa Tadahiro
- Department of Pediatrics, Sakakibara Heart Institute
-
- Murakami Yasuo
- Department of Pediatrics, Sakakibara Heart Institute
-
- Mori Katsuhiko
- Department of Pediatrics, Sakakibara Heart Institute
-
- Mimori Shigekazu
- Department of Cardiovascular Surgery, Sakakibara Heart Institute
-
- Ando Makoto
- Department of Cardiovascular Surgery, Sakakibara Heart Institute
-
- Takahashi Yukihiro
- Department of Cardiovascular Surgery, Sakakibara Heart Institute
-
- Doi Shouzaburo
- Department of Pediatrics, Tokyo Medical and Dental University
-
- Mizutani Shuuki
- Department of Pediatrics, Tokyo Medical and Dental University
-
- Nakanishi Toshio
- Department of Pediatric Cardiology, Heart Institute, Tokyo Women's Medical University
この論文をさがす
抄録
Background: The effect of carvedilol on heart failure (HF) in patients with a functionally univentricular heart (UVH) remains unclear. Methods and Results: Carvedilol was used to treat HF in 51 patients with a UVH, classified into 3 groups: after the Fontan operation (F), after the bidirectional Glenn operation (G), and patients who had not undergone Fontan or Glenn operation (NF). Carvedilol therapy was started at a mean age of 10±12 years (range: 1 month to 34 years). The initial and maximum doses of carvedilol were 0.04±0.03 and 0.42±0.29mg·kg-1·day-1, respectively. After a mean follow-up of 11 months, the cardiothoracic ratio improved from 60±8 to 58±8% (P<0.01), and the dosage of furosemide was reduced from 1.4±0.9 to 0.7±0.7mg·kg-1·day-1 (P<0.01). The ejection fraction also improved from 35±12 to 40±11% (P<0.05), and this improvement was prominent in the F group (from 35±15 to 45±9%; P<0.05). Clinical signs, symptoms, and New York Heart Association functional class also improved. Conclusions: Carvedilol may play an important role in treating HF associated with a UVH. (Circ J 2011; 75: 1394-1399)<br>
収録刊行物
-
- Circulation Journal
-
Circulation Journal 75 (6), 1394-1399, 2011
一般社団法人 日本循環器学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390282680079061888
-
- NII論文ID
- 10028148842
-
- NII書誌ID
- AA11591968
-
- COI
- 1:CAS:528:DC%2BC3MXot1Ghs7w%3D
-
- ISSN
- 13474820
- 13469843
-
- PubMed
- 21436593
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- Crossref
- PubMed
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可